ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25Q1, 26TTMFlujo de caja de las actividades de inversión8 000-2 000-3 000-7 00003 000-7 000Flujo de caja de las actividades financieras1.35 M9.17 M40 K2.02 M12.4 M014.47 MFlujo de caja libre-1.37 M-1.27 M-2.54 M-2.09 M-2.08 M-4 M-10.72 M
Phio Pharmaceuticals Corp. - Common Stock
Phio Pharmaceuticals Corporation is a US clinical stage biotechnology company developing its INTASYL siRNA in immuno-oncology. Formerly known as RXi Pharmaceuticals, the company's name was changed to Phio Pharmaceuticals in 2018.